The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
The proceeds from the QIP will be used primarily to accelerate the nationwide expansion of the COCO stores of Davaindia nationwide
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
Indian Pharmacopoeia is now recognised in 19 countries, reflecting growing international confidence in India’s regulatory and scientific capabilities
Nona aims to help global biopharmaceutical companies fast-track clinical trial initiation without compromising scientific rigor or quality standards
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
Subscribe To Our Newsletter & Stay Updated
